Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial?

[1]  S. Savitz,et al.  Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. , 2009, Stem cells and development.

[2]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[3]  F. Cosio,et al.  Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  W. Zhang,et al.  Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model. , 2007, Transplantation proceedings.

[5]  Stefanie Dimmeler,et al.  Cell-Based Therapy of Myocardial Infarction , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[6]  R. Robbins,et al.  Stem cell transplantation: the lung barrier. , 2007, Transplantation proceedings.

[7]  W. Sherman,et al.  Catheter-based delivery of cells to the heart , 2006, Nature Clinical Practice Cardiovascular Medicine.

[8]  Doris A Taylor,et al.  Cell–based cardiovascular repair , 2005, Basic Research in Cardiology.

[9]  Ernst J. Rummeny,et al.  Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[11]  Tomoko Nakanishi,et al.  ‘Green mice’ as a source of ubiquitous green cells , 1997, FEBS letters.

[12]  H. Ott,et al.  Cell-based cardiovascular repair--the hurdles and the opportunities. , 2005, Basic research in cardiology.